Since the initial trial, studies have produced mixed results, with a phase III trial of the EGFR inhibitor cetuximab in combination with gemcitabine showing no improvement over gemcitabine alone, as well as a recent phase III trial in resectable pancreatic cancer also showing no additional survival benefits with the erlotinib/gemcitabine combination over gemcitabine alone [15,16]. Here, EGFR is linked to familial pancreatic carcinoma.